FDA Orders Pfizer to Add PARALYSIS WARNING to RSV Vaccine Labels

“FDA conducted a post-marketing observational study that assessed the risk of GBS (paralysis and muscle weakness) following vaccination with Abrysvo (Pfizer) and Arexvy (GSK) RSV vaccines."

January 15, 2025: Last Wednesday, the FDA ordered Pfizer and GSK to add Guillain-Barre Syndrome (GBS) as a serious adverse event risk warning to both Pfizer’s Abrysvo and GSK’s Arexy Respiratory Syncytial Virus (RSV) vaccine labels.

RSV is the leading cause of respiratory infection in adults over the age of 60. Prior to 2023, the CDC has not published data on the incidence of RSV death in babies and children. In 2023, the CDC estimates that approximately 100 children under the age of 5 died from RSV. Despite these low numbers, the CDC recommends that pregnant women receive an RSV vaccine to ‘protect’ their baby from RSV.

Image: Pfizer’s Abrysvo RSV Vaccine website

The FDA describes GBS as, “a rare disorder in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis.”

GBS and Polio are Both Caused by Infected Nerve Cells

It’s important to note that GBS is caused by an infection and swelling of nerve cells along the spinal cord which can lead to paralysis (known as myelitis), as is polio. A technical term for polio is poliomyelitis.

It’s also important to note that the FDA met with BioPharma companies on October 22, 2020, to discuss the diseases that would be caused by the COVID-19 mRNA injections, including eleven (11) forms of neurological diseases (nerve damage), including paralysis (GBS), convulsions and seizures.

These include Guillain-Barre Syndrome, acute disseminated encephalomyelitis, transverse myelitis, encephalitis, myelitis, encephalomyelitis, encephalopathy, convulsions and strokes.

New RSV Warning Was Based on Post-FDA Approval Study Conducted by the FDA

Per the FDA website, “FDA conducted a post-marketing observational study that assessed the risk of GBS following vaccination with Abrysvo and Arexvy. The association between vaccination with Abrysvo and Arexvy and GBS was evaluated among Medicare beneficiaries 65 years of age and older. Using Medicare claims data, between May 2023 through July 2024, vaccinations with Abrysvo and Arexvy were identified through Current Procedural Terminology (CPT)/Healthcare Common Procedure Coding System (HCPCS) codes and National Drug Codes, and potential cases of hospitalized GBS among recipients of Abrysvo and Arexvy were identified through International Classification of Diseases (ICD) codes. GBS diagnoses in claims data were confirmed by medical record review when available.

The risks of GBS following vaccination with Abrysvo and Arexvy were assessed in self-controlled case series analyses using risk windows of 1 to 42 days post vaccination and control windows of 43 to 90 days post vaccination. The analyses of all GBS cases based on claims data suggest an increased risk of GBS during the 42 days following vaccination, with an estimated 9 excess cases of GBS per million doses of Abrysvo, and an estimated 7 excess cases of GBS per million doses of Arexvy administered to individuals 65 years of age and older.”

What This Means for the COVID-19 mRNA Injections

The Shots Will Be Recalled.

The lack of efficacy of the COVID-19 injections is now well known amongst an overwhelming percentage of Americans and the serious diseases, disabilities and deaths that the shots have caused appears to be known by the majority….Except for the employees of the CDC, NIH, and FDA (all departments of HHS), as well as Moderna and Pfizer (even though Pfizer recorded 5 million adverse events across 1.5 million patients).

After RFK Jr. is confirmed as Secretary of Health & Human Services, an FDA audit will immediately be conducted of US healthcare databases of individuals who received the COVID-19 injections and then were diagnosed with a disease, such as myocarditis or stroke. I don’t have a guess as to the breadth of the US databases and diseases that will be analyzed, but I am confident that RFK Jr. will conduct a sufficient and swift audit to have the COVID-19 mRNA injections recalled from the market within 100 days of taking office.

In regard to the emergency use authorization (EUA) for Pfizer’s childhood mRNA shots for children under the age of 12 (and as young as 6 months old), I predict that Pfizer will request the FDA revoke the EUA for children as COVID-19 is no longer (and never was) a public health threat in the pediatric population. This will happen within days of the new administration.

Ecclesiastes 3:15-17

Whatever is has already been, and what will be has been before; and God will call the past to account.

And I saw something else under the sun: In the place of judgment—wickedness was there, in the place of justice—wickedness was there.

I said to myself, “God will bring into judgment both the righteous and the wicked, for there will be a time for every activity, a time to judge every deed.”

The Kingston Report. TRUTH WINS.

If You’d Like to Further Support My Work

Mail: Karen Kingston/miFight Inc., 960 Postal Way #307, Vista, CA 92085

Buy me a coffee (Ko-fi)

The Kingston Report is reader-supported.

Consider becoming a paid subscriber to support me and my work.

Contact: I can be contacted via email at patriots@mifight.com.